By Evercyte GmbH
To get in touch with Evercyte GmbH, simply fill out the form below.
Subscribe to Supplier
Evercyte promoting telomerized cell advantages at Small New World symposium
Vienna, Austria: – Innovative biotech manufacturer Evercyte will be a prominent presence at the upcoming ‘Small New World’ joint symposium of the Austrian, Hungarian, Slovenian and Serbian societies for Extracellular Vesicles (EVs).
Evercyte will participate at the joint ASEV/HSEV/SiNEV/SrbEV meeting in Graz, Austria to share the latest insights from its research programs and to promote the advantages of telomerized hTERT cell lines and cell factories for standardized EV production.
Preserved cell function
The Evercyte event team at Small New World will be led by co-founder and COO/CSO Dr. Regina Grillari and will include research scientist and PhD candidate Alessia Brancolini, who will present a poster entitled ‘Immortalization of mesenchymal stromal cells by hTERT does not affect the functional properties of secreted extracellular vesicles’ highlighting the suitability of Evercyte’s telomerized cell lines for EV production.
Evercyte has established immortalized EV production cell lines under xeno-free conditions, with full documentation of any manipulation step and hence can be transferred to a GMP facility for generation of master cell banks that can be used for production of clinical-grade vesicles. Production cell lines include MSC derived from adipose-tissue ASC/TERT300, bone-marrow BM-MSC/TERT292, chorionic plate CP-MSC/TERT308, placental amnion P-MSC/TERT308, dental pulp DPSC/TERT334, and Wharton’s Jelly WJ-MSC/TERT273.
These immortalized cells are highly similar to the human primary cells of origin, but with research advantages such as longer lifespan.
Enrichment and characterization testing
Evercyte offers a range of additional services that include cell line development, lab-scale production of EVs from Evercyte’s cell portfolio or customer-derived cells, EV enrichment and characterization, testing biological activity of EV for functional properties such as anti-fibrotic, anti-inflammatory, and wound-healing.
Dr. Grillari commented: “We are promoting our immortalized cell lines for stable production of EVs. When comparing the morphology, expression of canonical surface markers of our ‘telomerized’ cells to their primary counterparts no changes were observed.”
“The audience in Graz will also be interested to hear that our hTERT immortalized cells maintain primary cell-like phenotype and characteristics, while showing extended lifespan, growing unlimitedly in vitro. Moreover, no full-length hTERT mRNA or protein was detected in the EVs derived from our immortalized MSCs,” she added.
About Evercyte GmbH
Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel cell lines for production of extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalogue of readily available cell lines for the production of extracellular vesicles from mesenchymal stromal cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.
By providing native extracellular vesicles from mesenchymal stromal cells Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs e.g. tissue targeting and targeted drug delivery.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com.
About Small New World 2023
The Austrian Society for Extracellular Vesicles (ASEV) regularly collaborates with similar societies across Europe to organize knowledge-sharing events. For Autumn 2023, it is teaming up with the Hungarian Section for Extracellular Vesicles (HSEV), Slovenian Network for Extracellular Vesicles (SiNEV) and Serbian Society of Extracellular Vesicles (SrbEV) to stage ‘Small New World’ as a conference for Southeastern European researchers and scientists involved in the study of microvesicles and exosomes.
Small New World will be a two-day event opening September 4 at the Medical University of Graz, Austria. More than 1000 posters have already been submitted to the conference which will also hear from a range of keynote speakers on topics that include diversity of EV sources, the relationships between purity and function, potential EV therapeutics, EV numbers and cargo, and recent methodology advances in EV analysis.